Search results for "nephrectomy"

showing 10 items of 111 documents

Clinical implications of a rare renal entity: Pleomorphic Hyalinizing Angiectatic Tumor (PHAT)

2017

Abstract Pleomorphic Hyalinizing Angiectatic Tumor (PHAT) is a rare benign lesion characterized by slow growth, infiltrative behavior and high rate of local recurrences. Only one case has been described in retroperitoneum, at renal hilum, but not involving pelvis or parenchyma. Here we present the first case of PHAT arising in the renal parenchyma. A nodular lesion in right kidney lower pole was diagnosed to a 61 year old woman. The patient underwent right nephrectomy. Microscopically, the lesion showed solid and pseudo-cystic components with hemorrhagic areas characterized by aggregates of ectatic blood vessels. Pleomorphic cells were characterized by large eosinophilic cytoplasm with irre…

0301 basic medicinePathologymedicine.medical_specialtymedicine.medical_treatment2734Pleomorphic Hyalinizing Angiectatic Tumor (PHAT)Renal tumorKidneyRenal hilumNephrectomyPathology and Forensic MedicineLesion03 medical and health sciences0302 clinical medicineEctasiaParenchymaEosinophilicmedicineHumansPartial nephrectomyKidneybusiness.industryKidney NeoplasmCell BiologyMiddle AgedKidney NeoplasmsNephrectomyTreatment Outcome030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisImmunohistochemistryFemalemedicine.symptombusinessHumanPathology - Research and Practice
researchProduct

The Small Size and Superficial Location Suggest That Laparoscopic Partial Nephrectomy Is the First Choice for the Treatment of Juxtaglomerular Cell T…

2021

BackgroundJuxtaglomerular cell tumor (JGCT) is a very rare disease, and surgical resection is the only possible way to cure this tumor. Open nephrectomy and partial nephrectomy have been reported to manage JGCTs with excellent results in the previous reviews. Laparoscopic surgery has been popularized in recent years, while critical issues associated with laparoscopic surgical management have been seldom reported. We summarized the JGCTs in our center to discover the optimal surgical management and its anatomic foundation.MethodsIn this retrospective study, we enrolled a total of 14 JGCT patients. All patients received surgeries and were followed up for up to 11 years. We mainly summarized t…

AdenomaAdultMaleLaparoscopic surgerymedicine.medical_specialtyAdolescentEndocrinology Diabetes and Metabolismmedicine.medical_treatmentsuperficial location030204 cardiovascular system & hematologyNephrectomyPlasma renin activityDiseases of the endocrine glands. Clinical endocrinologysmall sizeYoung Adult03 medical and health sciencesEndocrinologyPostoperative Complications0302 clinical medicinemedicineHumansCarcinoma Renal CellOriginal ResearchAgedRetrospective Studieslaparoscopic partial nephrectomybusiness.industryRetrospective cohort studyjuxtaglomerular cell tumorsMiddle AgedRC648-665medicine.diseaseMagnetic Resonance ImagingKidney NeoplasmsHypokalemiaNephrectomySurgeryBlood pressure030220 oncology & carcinogenesisFemaleLaparoscopymedicine.symptombusinessJuxtaglomerular cell tumorlaparoscopic ultrasoundRare diseaseFrontiers in Endocrinology
researchProduct

Immunoperoxidase Staining of Fine-Needle Aspiration Biopsies of Renal Cell Carcinoma Using Tumor-Specific Monoclonal Antibody

1987

In 30 nephrectomy specimens, fine needle aspiration biopsies (FNAB) were performed both in the tumor and in the macroscopically normal part of the kidney: 18 were well differentiated renal cell carcinoma (RCC), 6 were moderately differentiated RCC, 4 were poorly differentiated RCC, and 2 were oncocytomas. FNAB was also performed in a bone metastasis of RCC. FNAB materials were stained using the immunoperoxidase method with RCC-specific monoclonal antibody and were compared with the staining of frozen sections. In all cases where tumor-antigen expression could be demonstrated in the frozen sections, a FNAB had already proven positive. There were only 2 false-negative cases where sufficient c…

AdenomaPathologymedicine.medical_specialtymedicine.drug_classUrologymedicine.medical_treatmenturologic and male genital diseasesMonoclonal antibodyImmunoenzyme TechniquesAntigens NeoplasmRenal cell carcinomaBiopsymedicineHumansCarcinoma Renal CellFrozen section proceduremedicine.diagnostic_testImmunoperoxidasebusiness.industryBiopsy NeedleAntibodies Monoclonalmedicine.diseaseKidney Neoplasmsfemale genital diseases and pregnancy complicationsNephrectomyStainingFine-needle aspirationbusinessEuropean Urology
researchProduct

Primitive Neuroectodermal Tumor (PNET) of the kidney: a case report.

2004

Abstract Background A case of Primitive Neuroectodermal Tumor (PNET) of the kidney in a 27-year-old woman is presented. Few cases are reported in the literature with a variable, nonspecific presentation and an aggressive behaviour. In our case, a radical nephrectomy with lymphadenectomy was performed and there was no residual or recurrent tumour at 24-month follow-up. Methods The surgical specimens were formalin-fixed and paraffin embedded. The sections were stained with routinary H&E. Immunohistochemistry was performed. Results The immunohistochemical evaluation revealed a diffuse CD99 positivity in the cytoplasm of the neoplastic cells. Pankeratin, cytokeratin AE1/AE3, vimentin, desmin, S…

AdultEwing's SarcomaPNETCancer ResearchPathologymedicine.medical_specialtyRenal PNETmedicine.medical_treatmentCD99Case Reportlcsh:RC254-282Diagnosis DifferentialCytokeratinImmunophenotypingSurgical oncologystem cellsGeneticsmedicineHumansNeuroectodermal Tumors Primitive Peripheralrhabdomyosarcoma tumorbusiness.industryEwing's sarcomalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseNephrectomyKidney NeoplasmsOncologyPrimitive neuroectodermal tumorFemaleDifferential diagnosisbusinesscarcinogenesis
researchProduct

Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results

2019

Abstract Background This multi-institutional retrospective real life study was conducted in 22 Italian Oncology Centers and evaluated the role of Axitinib in second line treatment in not selected mRCC patients. Methods 148 mRCC patients were evaluated. According to Heng score 15.5%, 60.1% and 24.4% of patients were at poor risk, intermediate and favorable risk, respectively. Results PFS, OS, DCR and ORR were 7.14 months, 15.5 months, 70.6% and 16.6%, respectively. The duration of prior sunitinib treatment correlated with a longer significant mPFS, 8.8 vs 6.3 months, respectively. Axitinib therapy was safe, without grade 4 adverse events. The most frequent toxicities of all grades were: fati…

AdultMale0301 basic medicineOncologymedicine.medical_specialtyMultivariate analysisAxitinibAxitinib; Metastatic; Renal cancer; Sunitinib; Treatmentmedicine.medical_treatmentPopulationlcsh:MedicineKaplan-Meier EstimateDisease-Free SurvivalGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineInternal medicineSunitinibHumansMedicineNeoplasm MetastasiseducationAdverse effectMetastatic renal cell cancerCarcinoma Renal CellAgedAged 80 and overSecond-line therapyeducation.field_of_studybusiness.industrySunitinibResearchlcsh:RGeneral MedicineMiddle AgedKidney NeoplasmsNephrectomyAxitinibTreatment030104 developmental biologyRenal cancer030220 oncology & carcinogenesisMultivariate AnalysisMetastaticFemalebusinessmedicine.drugJournal of Translational Medicine
researchProduct

Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma--a multicentre study.

2012

Abstract Aim of the study Papillary renal cell carcinoma (pRCC) is the second most common subtype of RCC after the conventional clear cell type (cRCC). However, its characteristics and prognosis have been less intensively investigated. The aim of our study was to examine the tumour characteristics and long-term prognosis of pRCC compared to clear cell RCC (cRCC). Methods In total, 4941 evaluable patients were subjected to either radical nephrectomy or nephron-sparing surgery for pRCC or cRCC at five centres in Germany (University Hospitals of Hannover, Homburg/Saar, Mainz, Ulm and Marburg) between 1990 and 2010. Results pRCC ( n  = 565) and cRCC ( n  = 4376) patients were comparable with re…

AdultMaleCancer Researchmedicine.medical_specialtyPathologymedicine.medical_treatmentGastroenterologyYoung AdultInternal medicineGermanyCarcinomaMedicineHumansSurvival rateCarcinoma Renal CellAgedRetrospective StudiesAged 80 and overPapillary renal cell carcinomasbusiness.industryIncidenceMiddle Agedmedicine.diseasePrognosisNephrectomyKidney NeoplasmsSurvival RateClear cell renal cell carcinomaOncologyClear cell carcinomaFemalebusinessKidney cancerClear cellEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Short-Term Functional and Oncologic Outcomes of Nephron-Sparing Surgery for Renal Tumours ≥7cm

2011

Abstract Background Nephron-sparing surgery (NSS) for renal tumours preserves renal function and has become the standard approach for small renal tumours. Little is known about perioperative and oncologic outcomes of patients following NSS in renal tumours ≥7cm in the presence of a healthy contralateral kidney. Objective To analyse oncologic outcomes and perioperative morbidity in patients treated by NSS for renal tumours ≥7cm. Design, setting, and participants In total, 5767 patients were treated for renal tumours at two institutions from 1984 to 2009. In 91 patients, elective NSS was performed for renal tumours ≥7cm. Measurements Complication rates were assessed in detail and stratified u…

AdultMaleNephrologymedicine.medical_specialtyTime FactorsUrologymedicine.medical_treatmentKaplan-Meier EstimateNephrectomyRisk AssessmentDisease-Free SurvivalRisk FactorsRenal cell carcinomaGermanyInternal medicinemedicineHumansMinimally Invasive Surgical ProceduresSurvival rateAgedNeoplasm StagingRetrospective StudiesAged 80 and overUnivariate analysisbusiness.industryPatient SelectionPerioperativeMiddle Agedmedicine.diseaseKidney NeoplasmsNephrectomyTumor BurdenSurgerySurvival RateLogistic ModelsTreatment OutcomeFemalebusinessKidney cancerKidney diseaseEuropean Urology
researchProduct

Bilateral synchronous sporadic renal cell carcinoma: surgical management, oncological and functional outcomes

2007

OBJECTIVE To analyse the functional and oncological outcomes of surgical treatment of bilateral synchronous sporadic renal cell carcinoma (RCC). PATIENTS AND METHODS Between 1969 and 2006, 57 patients with bilateral synchronous sporadic RCC were identified from our kidney database. The mean (range) follow-up was 4.8 (0.1–23.8) years; 28 patients (49%) had radical nephrectomy (RN) and contralateral nephron-sparing surgery (NSS), and 22 (39%) had bilateral NSS. The oncological outcome and long-term renal function were analysed. RESULTS After excluding four patients (7%) with bilateral benign renal tumours, six (11%) with metastatic bilateral RCC and three (5%) who had bilateral RN, the cancer…

AdultMaleNephrologymedicine.medical_specialtyUrologymedicine.medical_treatmentRenal functionurologic and male genital diseasesNephrectomyNeoplasms Multiple PrimaryRenal cell carcinomaInternal medicineCarcinomaHumansMedicineCarcinoma Renal CellDialysisAgedNeoplasm StagingAged 80 and overbusiness.industryNephronsMiddle AgedPrognosismedicine.diseaseSurvival AnalysisKidney NeoplasmsNephrectomySurgeryTreatment OutcomeFemalebusinessKidney cancerFollow-Up StudiesKidney diseaseBJU International
researchProduct

Small renal cell carcinomas – How dangerous are they really? Results of a large multicenter study

2013

Modern diagnostic ultrasound and cross-sectional imaging has enabled the detection of increasing numbers of renal tumours. The aim of this study was to investigate the tumour- and patient-specific characteristics and prognosis of small renal cell carcinomas (RCCs) after surgical resection.The study included 2197 patients who underwent surgical resection of histologically confirmed RCC ⩽ 4 cm between 1990 and 2011. Median (mean) follow-up was 56.2 (65.5) months.At the time of surgery, tumours were staged as pT ⩾ 3a in 175 (8.0%) cases, 134 (6.2%) were poorly differentiated and 75 (3.5%) were metastasised. The larger the tumour size, the higher was the risk of presenting with stage pT ⩾ 3a (p…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyAdolescentCellNephrectomyGastroenterologyMetastasisYoung AdultInternal medicinemedicineHumansStage (cooking)Risk factorCarcinoma Renal CellPathologicalAgedNeoplasm StagingAged 80 and overbusiness.industryMortality rateMiddle Agedmedicine.diseaseSurvival AnalysisKidney NeoplasmsTumor Burdenmedicine.anatomical_structureOncologyMulticenter studyFemalebusinessKidney cancerFollow-Up StudiesEuropean Journal of Cancer
researchProduct

The Influence of the Primary Tumor on the Long-term Results of Pulmonary Metastasectomy for Metastatic Renal Cell Carcinoma

2011

OBJECTIVE To investigate one of the primary tumor (PT) on pulmonary metastasectomy (PM) for metastatic renal cell carcinoma (RCC) and to define prognostic factors. METHODS Retrospective review of patients with pulmonary metastases from RCC from January 1999 through December 2008 was performed. All patients underwent PM with curative intend. TNM-classification, tumor stage and PT grade, disease-free-interval (DFI) from nephrectomy to the diagnosis of metastasis, systemic chemotherapy before surgical intervention, surgical procedures, morbidity, mortality, and survival were investigated. RESULTS One-hundred seven consecutive patients (age 61.5 ± 9.6 years) underwent PM. Morbidity and mortalit…

AdultMalePulmonary and Respiratory MedicineOncologymedicine.medical_specialtyLung NeoplasmsTime Factorsmedicine.medical_treatmentUrologyKaplan-Meier EstimateNephrectomyRisk AssessmentRisk FactorsRenal cell carcinomaInternal medicinemedicineAdjuvant therapyHumansPneumonectomyCarcinoma Renal CellAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesAged 80 and overUnivariate analysisProportional hazards modelbusiness.industryMortality rateMetastasectomyMiddle Agedmedicine.diseasePrimary tumorKidney NeoplasmsNeoadjuvant TherapyNephrectomyTreatment OutcomeChemotherapy AdjuvantLymphatic MetastasisMultivariate AnalysisFemaleSurgeryNeoplasm GradingMetastasectomyCardiology and Cardiovascular MedicinebusinessThe Thoracic and Cardiovascular Surgeon
researchProduct